March 24th 2017
Whereas the androgen receptor (AR) is a common target in prostate cancer, emerging findings are showing a potential role for targeting AR in breast cancer, as well.
March 13th 2017
Michael F. Press, MD, PhD, discusses issues with the ASCO-CAP guidelines on assessment of HER2 amplification by fluorescence in situ hybridization testing.
February 20th 2017
Dr. Elizabeth Swisher discusses biomarkers for PARP inhibitors and the evolving role of these agents in ovarian cancer.
February 17th 2017
Results of a phase I expansion study demonstrated a manageable safety profile and clinical activity with mirvetuximab soravtansine in the treatment of patients with platinum-resistant ovarian cancer.
February 13th 2017
Rovalpituzumab tesirine demonstrated encouraging single-agent antitumor activity with a manageable safety profile in the treatment of patients with recurrent small cell lung cancer.
February 10th 2017
Intentional weight loss in postmenopausal women has been found to be associated with a lower endometrial cancer risk, particularly among those with obesity, according to the results of a recent study published in the Journal of Clinical Oncology.
February 8th 2017
Anne Rositch, PhD, discusses important takeaways from her study on hysterectomy-corrected mortality rates in cervical cancer and the significance of cervical cancer screening.
February 6th 2017
The addition of hormonal therapy to radiation treatment following surgery significantly improved survival in patients with recurrent prostate cancer, according to the results of a study published in The New England Journal of Medicine.
January 28th 2017
Diagnostic laparoscopy reduced the number of futile laparotomies in patients with suspected advanced-stage ovarian cancer, according to the results of a recent study.
January 27th 2017
A prostate-specific antigen nadir greater than 0.5 ng/mL following radiation and androgen deprivation therapy seems to identify men prior to PSA failure who are at high-risk for death, and would thus require more aggressive treatment for their prostate cancer.
January 26th 2017
Lois Ramondetta, MD, discusses the updated recommendations and the importance of advocating for lesser-known HPV-associated cancers.
January 24th 2017
Carolyn E. Banister, MD, discusses the results of a study that uncovered a new subtype of cervical cancer, as well as some of the remaining challenges in the overall treatment landscape.
January 19th 2017
A sharp decline has been observed in the overall rate of men receiving treatment for prostate cancer.
A direct assessment of the uterine microbiome in patients with endometrial cancer has revealed a potential predictive role for vaginal microbes.
January 18th 2017
A watch-and-wait approach is emerging as a potential treatment strategy for patients with rectal cancer.
January 14th 2017
In the current treatment landscape of HPV-positive oropharyngeal squamous cell carcinoma, there is a significant lack of biomarkers to predict recurrence.
As mortality rates continue to climb in endometrial cancer, there remains a pressing need for effective screening and diagnostics.
January 13th 2017
Anti-HER2 DC1 vaccination was demonstrated to be a safe and immunogenic treatment to induce tumor-specific T-cell responses in patients with HER2-positive breast cancer.
January 11th 2017
Roy Herbst, MD, PhD, discusses the next steps with pembrolizumab in NSCLC, PD-L1 testing, and managing increased toxicities with combination regimens.
January 9th 2017
According to Dimosthenis Andreou, MD, patients with pelvic Ewing sarcoma have poorer local control and poorer overall survival.